ATTORNEY DOCKET NO.: 056291-5038

Application No.: 09/889,409

Page 2

STATUS OF CLAIMS:

For the Examiner's convenience, even though <u>no claims are being amended herein</u>, the status of all claims and text of all pending claims is presented below in accordance with the new procedures:

Claims 1-21 (cancelled).

Claim 22 (previously added): A method for treating diabetic neuropathy in a warm blooded animal in need thereof comprising administering to said animal a treatment-effective amount of the statin drug (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino] pyrimidin-5-yl] (3R,5S)-3,5-dihydroxyhept-6-enoic acid or a pharmaceutically acceptable salt thereof.

Claim 23 (cancelled).

Claim 24 (previously added): The method as claimed in claim 22 or 42 wherein the statin drug is administered as a pharmaceutical combination additionally comprising at least one other drug used for treating diabetes or the complications of diabetes.

Claim 25 (previously added): The method as claimed in claim 24 wherein the at least one other drug used for treating diabetes or the complications of diabetes is selected from insulin, troglitazone, rosiglitazone, pioglitazone, MCC-555, (S)-2-ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl}ethoxy)phenyl]propanoic acid and 3-{4-[2-(4-tert-butoxycarbonylaminophenyl)ethoxy]phenyl}-(S)-2-ethoxy propanoic acid, glimepiride, glibenclamide, gliclazide, glipizide, gliquidone and tolazamide, metformin, acarbose and repaglinide.

Claims 26-41 (cancelled).

ATTORNEY DOCKET NO.: 056291-5038

Application No.: 09/889,409

Page 3

Claim 42 (previously added): A method as claimed in claim 22 wherein the statin drug is the calcium salt of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino] pyrimidin-5-yl] (3R,5S)-3,5-dihydroxyhept-6-enoic acid.

Claim 43 (previously added): A method as claimed in claim 24 wherein the at least one other drug used for treating diabetes or the complications of diabetes is an insulin sensitising agent.

Claim 44 (previously added): A method as claimed in claim 43 wherein the insulin sensitising agent is (S)-2-ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl}ethoxy)phenyl]propanoic acid.

Claim 45 (previously added): A method as claimed in claim 24 wherein the drugs are administered separately in individual dosage forms together or sequentially.

Claim 46 (previously added): A method as claimed in claim 24 wherein the drugs are administered in the same unit dosage form.

Claim 47 (previously added): A method as claimed in claim 22 or 42 wherein 5 mg to 80 mg of the statin drug is administered.

Claim 48 (previously added): A method as claimed in claim 24 wherein the drugs are administered orally.